Targeted exome sequencing for the identification of common mutational signatures and potential driver mutations for brain metastases and prognosis

Zhang, Dainan; Wang, Xi; Ma, Shunchang; Li, Peiliang; Xue, Fei; Mao, Beibei; Guan, Xiudong; Zhou, Wenjianlong; Peng, Jiayi; Su, Kun; Zhang, Chuanbao ✉; Jia, Wang ✉

Angol nyelvű Tudományos Szakcikk (Folyóiratcikk)
Megjelent: ONCOLOGY LETTERS 1792-1074 1792-1082 21 (3) Paper: 179 , 8 p. 2021
  • SJR Scopus - Cancer Research: Q3
Azonosítók
Brain metastases (BMs) are malignancies in the central nervous system with poor prognosis. Genetic landscapes of the primary tumor sites have been extensively profiled; however, mutations associated with BMs are poorly understood. In the present study, target exome sequencing of 560 cancer-associated genes in samples from 52 patients with brain metastasis from various primary sites was performed. Recurrent mutations for BMs from distinct origins were identified. There were both genetic homogeneity and heterogeneity between BMs and primary lung tumor tissues. The mutation rate of the major cancer driver gene, TP53, was consistently high in both the primary lung cancer sites and BMs, while some genetic alterations, associated with DNA damage response deficiency, were specifically enriched in BMs. The mutational signatures enriched in BMs could serve as actionable targets for treatment. The mutation in the primary site of the potential brain metastasis driver gene, nuclear mitotic apparatus protein 1 (NUMA1), affected the progression-free survival time of patients with lung cancer, and patients with the NUMA1 mutation in BMs had a good prognosis. This suggested that the occurrence and clinical outcome of brain metastases could be independent of each other.
Hivatkozás stílusok: IEEEACMAPAChicagoHarvardCSLMásolásNyomtatás
2022-01-25 02:57